Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
TNBC
breast cancer
microbiome
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
07 09 2023
07 09 2023
Historique:
received:
19
08
2022
accepted:
31
01
2023
medline:
11
9
2023
pubmed:
21
3
2023
entrez:
20
3
2023
Statut:
ppublish
Résumé
Patients with triple-negative breast cancer (TNBC) achieving a pathological complete response (pCR) after neoadjuvant chemotherapy have a better event-free survival. The role of gut microbiome in early TNBC is underexplored. Microbiome was analyzed by 16SrRNA sequencing. Twenty-five patients with TNBC treated with neoadjuvant anthracycline/taxane-based chemotherapy were included. Fifty-six percent achieved a pCR. Fecal samples were collected before (t0), at 1 (t1), and 8 weeks (t2) from chemotherapy. Overall, 68/75 samples (90.7%) were suitable for microbiome analysis. At t0, pCR group showed a significantly higher α-diversity as compared with no-pCR, (P = .049). The PERMANOVA test on β-diversity highlighted a significant difference in terms of BMI (P = 0.039). Among patients with available matched samples at t0 and t1, no significant variation in microbiome composition was reported over time. Fecal microbiome analysis in early TNBC is feasible and deserves further investigation in order to unravel its complex correlation with immunity and cancer.
Identifiants
pubmed: 36940301
pii: 7081221
doi: 10.1093/oncolo/oyad060
pmc: PMC10485294
doi:
Substances chimiques
Anthracyclines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e703-e711Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Nat Med. 2022 Apr;28(4):690-703
pubmed: 35440726
Int J Mol Sci. 2021 Jun 30;22(13):
pubmed: 34208885
Genes (Basel). 2019 Aug 19;10(8):
pubmed: 31430963
Cell Host Microbe. 2012 Oct 18;12(4):496-508
pubmed: 23084918
Cell Death Differ. 2021 Sep;28(9):2778-2796
pubmed: 33963313
J Transl Med. 2017 Apr 8;15(1):73
pubmed: 28388917
Ann Appl Stat. 2020 Mar;14(1):94-115
pubmed: 32983313
PeerJ. 2018 Apr 2;6:e4600
pubmed: 29629248
Cytokine. 2006 Dec;36(5-6):254-60
pubmed: 17363262
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Cell. 2016 Apr 7;165(2):276-87
pubmed: 27058662
Science. 2021 Dec 24;374(6575):1632-1640
pubmed: 34941392
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
mSystems. 2018 May 15;3(3):
pubmed: 29795809
Microbiome. 2020 Mar 5;8(1):28
pubmed: 32138779
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Med Sci Monit. 2004 Apr;10(4):BR96-104
pubmed: 15039638
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Cancer Cell. 2015 Dec 14;28(6):687-689
pubmed: 26678336
Science. 2013 Nov 22;342(6161):971-6
pubmed: 24264990
Oncol Lett. 2014 May;7(5):1738-1742
pubmed: 24765211
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Ann Oncol. 2015 Sep;26 Suppl 5:v139-51
pubmed: 26142468
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
PLoS One. 2013 Jul 15;8(7):e68739
pubmed: 23869230
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Science. 2013 Nov 22;342(6161):967-70
pubmed: 24264989